First Trust Large Cap Growth Fund logo

First Trust Large Cap Growth Fund (FTC)

Market Closed
22 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
179. 05
-0.11
-0.0593%
$
1.41B Market Cap
0.21% Div Yield
80,850 Volume
$ 179.16
Previous Close
Add Transaction
Day Range
177.56 179.94
Year Range
147.94 194.18
Want to track FTC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
FTC antitrust lawsuit against Amazon will proceed, some claims dropped

FTC antitrust lawsuit against Amazon will proceed, some claims dropped

The Federal Trade Commission's antitrust lawsuit against Amazon will proceed, though some claims have been dropped, following a ruling from a federal district judge.

Techxplore | 1 year ago
The extent of Amazon's ‘partial victory' against the FTC is under wraps for now

The extent of Amazon's ‘partial victory' against the FTC is under wraps for now

A federal judge in Seattle granted in part, and denied in part, Amazon's motion to dismiss the U.

Geekwire | 1 year ago
Amazon just won a partial victory against the FTC

Amazon just won a partial victory against the FTC

Amazon won partial dismissal of an FTC lawsuit alleging illegal monopoly practices. The FTC accused Amazon of stifling competition by coercing sellers to use its service.

Businessinsider | 1 year ago
FTC Clears Chevron-Hess Merger, But Bans Hess CEO From Joining Board

FTC Clears Chevron-Hess Merger, But Bans Hess CEO From Joining Board

The Federal Trade Commission (FTC) on Monday cleared Chevron's (CVX) $53 billion acquisition of Hess (HES), but barred Hess CEO John Hess from joining Chevron's board, citing concerns about his previous communications with Organization of Petroleum Exporting Countries (OPEC) officials.

Investopedia | 1 year ago
FTC clears Chevron-Hess deal, bans John Hess from board

FTC clears Chevron-Hess deal, bans John Hess from board

The FTC on Monday alleged that John Hess encouraged senior officials at OPEC to draw down inventories, which would result in higher oil prices. Hess Corp. and Chevron have agreed that they will not appoint Hess to the board in order to facilitate the completion of the merger.

Cnbc | 1 year ago
FTC allows Chevron-Hess deal, bars John Hess from board

FTC allows Chevron-Hess deal, bars John Hess from board

The U.S. Federal Trade Commission allowed Chevron's $53 billion purchase of Hess Corp on Monday, in an order that barred Hess CEO John Hess from Chevron's board.

Reuters | 1 year ago
FTC Plans to Block Hess CEO from Chevron Board

FTC Plans to Block Hess CEO from Chevron Board

John Hess would be prevented from Chevron's board as part of deal for antitrust approval of a Hess-Chevron merger.

Wsj | 1 year ago
Promises of 'passive income' on Amazon led to death threats for negative online review, FTC says

Promises of 'passive income' on Amazon led to death threats for negative online review, FTC says

The Federal Trade Commission is cracking down on "automation" companies that launch and manage online businesses on behalf of customers in exchange for an upfront investment. The latest case targets Ascend Ecom, which ran an e-commerce money-making scheme, primarily on Amazon.

Cnbc | 1 year ago
FTC set to greenlight chevron's $53 billion buy of oil rival Hess, sources say

FTC set to greenlight chevron's $53 billion buy of oil rival Hess, sources say

The U.S. Federal Trade Commission is expected to greenlight U.S. oil producer Chevron's purchase of Hess as soon as this week, two people familiar with the matter said, leaving Exxon Mobil's challenge to the $53 billion deal as its final hurdle.

Reuters | 1 year ago
FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice'

FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice'

Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.

Marketwatch | 1 year ago
FTC Sues CVS, Cigna, UnitedHealth Over Insulin Costs

FTC Sues CVS, Cigna, UnitedHealth Over Insulin Costs

The US Federal Trade Commission is accusing units of CVS, Cigna, and UnitedHealth of engaging in illegal rebate programs that drove up the price of insulin. Federal Trade Commission Office of Public Affairs Director Douglas Farrar discusses the lawsuit against the pharmacy benefits managers.

Youtube | 1 year ago
FTC sues drug middlemen for allegedly inflating insulin prices

FTC sues drug middlemen for allegedly inflating insulin prices

The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen boost their profits while "artificially" inflating costs for patients.  The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts, and their affiliated group purchasing organizations.

Cnbc | 1 year ago
Loading...
Load More